Biofrontera (BFRI) Total Debt (2021 - 2024)

Biofrontera (BFRI) posted quarterly Total Debt of $296000.0 for Q2 2024, down 87.43% quarter-over-quarter from $2.4 million in Q1 2024.

Biofrontera (BFRI) Total Debt (2021 - 2024) Analysis & Trends

Biofrontera's Total Debt history runs 4 years deep, the most recent figure standing at $296000.0 for Q2 2024.

In Q2 2024, Total Debt changed N/A year-over-year to $296000.0; the TTM figure through Jun 2024 stood at $296000.0 (changed N/A YoY), while the FY2023 annual figure was $3.9 million, down 43.76% from the prior year.
Total Debt for Q2 2024 stood at $296000.0, down from $2.4 million in the prior quarter.
The five-year high for Total Debt was $7.0 million in Q1 2023, with the low at $296000.0 in Q2 2024.
The 4-year median for Total Debt is $3.2 million (2021), against an average of $3.6 million.
The sharpest annual moves came in 2022 and 2024: Total Debt surged 114.13% in 2022, then slumped 66.51% in 2024.
Biofrontera's Total Debt stood at $3.2 million in 2021, then surged by 114.13% to $6.9 million in 2022, then slumped by 43.76% to $3.9 million in 2023, then slumped by 92.42% to $296000.0 in 2024.
Business Quant data shows BFRI's Total Debt at $296000.0 in Q2 2024, $2.4 million in Q1 2024, and $3.9 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	-5.81 Bn
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	16.59 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	9.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	31.47 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	-
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	13.35 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	-
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	3.92 Bn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	760.00 Mn
10	Biofrontera	18.87 Mn	14.16 Mn	9.59 Mn	-

Download Data